国产异长春花碱与顺铂联合治疗老年晚期非小细胞肺癌的临床观察

Clinical Observations on Elderly Patients with Advanced Non-small Cell Lung Cancer Treated with Vinorelbin and Cisplatin

目的:评价国产异长春花碱(艾克宁)与顺铂(DDP)联合治疗老年(大于65岁)晚期非小细胞肺癌(NSCLC)患者的疗效与安全性。方法:艾克宁25mg/m2静脉注入第1、第8天,顺铂30mg/m2静脉滴注第1天～第3天,每3周～4周为1周期,治疗晚期NSCLC患者63例,A组(>65岁)33例;B组(<65岁)30例。结果:A、B两组有效率分别为45.5%(15/33)、46.7%(14/30),无显著性差异(P>0.05),主要毒性为骨髓抑制、白细胞减少Ⅲ～Ⅳ度发生率A、B两组分别为54.5%(18/33)、46.7%(14/30),无显著性差异(P>0.05),胃肠道反应发生率A、B两组分别为54.5%(18/33)、60.0%(18/30),无显著性差异(P>0.05)。结论:艾克宁与DDP联合治疗老年晚期非小细胞肺癌患者,与非老年患者有同样好的疗效与安全性。

OBJECTIVE： To evaluate the efficacy and safety of vinorelbine （VRB） in combination with cisplatin （DDP） in the treatment of elderly patients （aged over 65 years） with advanced non - small cell lung cancer （NSCLC）. METHODS： A total of 63 patients with advanced NSCLC were enrolled： 33 aged over 65 years were assigned to group A, and 30 aged less than 65 years were assigned to group B. The patients were administered with NVB 25 mg/m^2 iv gtt on days 1 and 8 plus DDP 30 mg/m^2 iv gtt from the first day to the third day, with 3 - 4 weeks as 1 cycle of therapy. RESULTS ： The responsive rates of group A and B were 45.5% （15/33） and 46.7% （14/30）, respectively, and no significant difference were noted between the two groups （P 〉 0.05 ）. Myelosuppression was the chief toxic reactions; incidences of Grade Ⅲ - Ⅳ leucopenia in group A and B were 54.5% （18/33） and 46.7% （14/30）, respectively, and there was no significant differences between the two groups （ P 〉 0.05）, and incidences of gastrointestinal tracts in group A and B were 54.5 % （18/ 33） and 60.0% （18/30） respectively, and there was no significant difference between the two groups （P 〉 0.05）. CONCLUSION： NVB and DDP used concomitantly showed a same satisfactory efficacy and safety in elderly （ 〉 65 years） patients with advanced NSCLC as in those less than 65 years with advanced NSCLC.